- ### OntologyBlock
  id:: drug-discovery-ai-ontology
  collapsed:: true
	- ontology:: true
	- term-id:: AI-0341
	- preferred-term:: Drug Discovery AI
	- source-domain:: mv
	- status:: draft
- definition:: Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.


## OWL Formal Semantics

```clojure
;; OWL Functional Syntax

(Declaration (Class :DrugDiscoveryAi))

;; Annotations
(AnnotationAssertion rdfs:label :DrugDiscoveryAi "Drug Discovery AI"@en)
(AnnotationAssertion rdfs:comment :DrugDiscoveryAi "Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates."@en)

;; Semantic Relationships
(SubClassOf :DrugDiscoveryAi
  (ObjectSomeValuesFrom :relatedTo :MolecularDesign))
(SubClassOf :DrugDiscoveryAi
  (ObjectSomeValuesFrom :relatedTo :GraphNeuralNetwork))
(SubClassOf :DrugDiscoveryAi
  (ObjectSomeValuesFrom :relatedTo :MedicalAi))
(SubClassOf :DrugDiscoveryAi
  (ObjectSomeValuesFrom :implements :GenerativeModels))

;; Data Properties
(AnnotationAssertion dcterms:identifier :DrugDiscoveryAi "AI-0341"^^xsd:string)
(DataPropertyAssertion :isAITechnology :DrugDiscoveryAi "true"^^xsd:boolean)
```

## Core Characteristics

- **Molecular Design**: De novo drug design and lead optimisation
- **Virtual Screening**: High-throughput computational screening of compound libraries
- **Target Prediction**: Identification of disease-relevant biological targets
- **ADMET Prediction**: Absorption, distribution, metabolism, excretion, toxicity forecasting
- **Clinical Trial Design**: Patient stratification and endpoint prediction

## Relationships

- **Superclass**: Medical AI
- **Related**: Cheminformatics, Bioinformatics, Molecular Modelling
- **Utilises**: Graph Neural Networks, Generative Models, Reinforcement Learning

## Technical Implementation

```python
import torch
import torch.nn as nn
from rdkit import Chem
from rdkit.Chem import Descriptors
from typing import List, Dict, Tuple

class DrugDiscoveryAI:
    """AI system for drug discovery and molecular design"""

    def __init__(self):
        self.molecular_property_predictor = self._load_property_model()
        self.generative_model = self._load_generative_model()

    def predict_molecular_properties(
        self,
        smiles: str
    ) -> Dict[str, float]:
        """Predict drug-like properties from SMILES notation"""
        mol = Chem.MolFromSmiles(smiles)

        properties = {
            'molecular_weight': Descriptors.MolWt(mol),
            'logP': Descriptors.MolLogP(mol),
            'hbd': Descriptors.NumHDonors(mol),
            'hba': Descriptors.NumHAcceptors(mol),
            'tpsa': Descriptors.TPSA(mol),
            'rotatable_bonds': Descriptors.NumRotatableBonds(mol)
        }

        # Lipinski's Rule of Five
        properties['lipinski_violations'] = sum([
            properties['molecular_weight'] > 500,
            properties['logP'] > 5,
            properties['hbd'] > 5,
            properties['hba'] > 10
        ])

        # AI-predicted properties
        properties['bioavailability'] = self._predict_bioavailability(mol)
        properties['toxicity_score'] = self._predict_toxicity(mol)
        properties['binding_affinity'] = self._predict_binding_affinity(mol)

        return properties

    def generate_drug_candidates(
        self,
        target_properties: Dict,
        num_candidates: int = 100
    ) -> List[str]:
        """Generate novel drug candidates with desired properties"""
        candidates = []

        for _ in range(num_candidates):
            # Generate SMILES using generative model
            smiles = self._generate_smiles(target_properties)

            # Validate and check properties
            if self._is_valid_drug_candidate(smiles, target_properties):
                candidates.append(smiles)

        return candidates

    def _predict_bioavailability(self, mol) -> float:
        """Predict oral bioavailability"""
        # Simplified - would use trained ML model
        return 0.75

    def _predict_toxicity(self, mol) -> float:
        """Predict toxicity score"""
        # Simplified - would use QSAR model
        return 0.2

    def _predict_binding_affinity(self, mol) -> float:
        """Predict target binding affinity"""
        # Simplified - would use docking or ML model
        return -8.5

    def _load_property_model(self) -> nn.Module:
        """Load molecular property prediction model"""
        return nn.Sequential()

    def _load_generative_model(self) -> nn.Module:
        """Load generative model for molecular design"""
        return nn.Sequential()

    def _generate_smiles(self, target_properties: Dict) -> str:
        """Generate SMILES notation for novel molecule"""
        # Simplified - would use VAE or GAN
        return "CC(C)CC1=CC=C(C=C1)C(C)C(=O)O"

    def _is_valid_drug_candidate(
        self,
        smiles: str,
        target_properties: Dict
    ) -> bool:
        """Validate drug candidate against target properties"""
        mol = Chem.MolFromSmiles(smiles)
        if mol is None:
            return False

        props = self.predict_molecular_properties(smiles)

        # Check Lipinski violations
        if props['lipinski_violations'] > 1:
            return False

        # Check target constraints
        for prop, target_value in target_properties.items():
            if prop in props:
                if abs(props[prop] - target_value) > target_value * 0.2:
                    return False

        return True


# Example usage
if __name__ == "__main__":
    drug_ai = DrugDiscoveryAI()

    # Analyse existing molecule
    aspirin_smiles = "CC(=O)OC1=CC=CC=C1C(=O)O"
    properties = drug_ai.predict_molecular_properties(aspirin_smiles)
    print(f"Aspirin properties: {properties}")

    # Generate new candidates
    target_props = {
        'molecular_weight': 350,
        'logP': 3.0,
        'bioavailability': 0.8
    }
    candidates = drug_ai.generate_drug_candidates(target_props, num_candidates=10)
    print(f"Generated {len(candidates)} drug candidates")
```

## Applications

1. **De Novo Drug Design**: Generation of novel molecular structures
2. **Virtual Screening**: Computational screening of compound libraries
3. **Lead Optimisation**: Optimisation of drug candidate properties
4. **Target Identification**: Discovery of disease-relevant targets
5. **Drug Repurposing**: Identification of new uses for existing drugs
6. **Toxicity Prediction**: Early-stage safety assessment
7. **Clinical Trial Design**: Patient selection and outcome prediction
8. **Formulation Optimisation**: Drug delivery system design

## Key Literature

1. Vamathevan, J., et al. (2019). "Applications of machine learning in drug discovery and development." *Nature Reviews Drug Discovery*, 18(6), 463-477.

2. Schneider, P., et al. (2020). "Rethinking drug design in the artificial intelligence era." *Nature Reviews Drug Discovery*, 19(5), 353-364.

3. Stokes, J. M., et al. (2020). "A deep learning approach to antibiotic discovery." *Cell*, 180(4), 688-702.

4. Zhavoronkov, A., et al. (2019). "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 37(9), 1038-1040.

## See Also

- [[Medical AI]]
- [[Molecular Design]]
- [[Generative Models]]
- [[Graph Neural Network]]

## Metadata

- **Domain**: Drug Discovery, Pharmaceutical Research
- **Maturity**: Research and early commercial deployment
	- maturity:: draft
	- owl:class:: mv:DrugDiscoveryAI
	- owl:physicality:: ConceptualEntity
	- owl:role:: Concept
	- belongsToDomain:: [[MetaverseDomain]]
	- #### Relationships
	  id:: drug-discovery-ai-relationships
- ## About Drug Discovery AI
	- Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.

	- ### Research
		- **[Open Molecules 2025](https://www.semafor.com/news/2025/05/21/meta-releases-huge-data-set-to-spur-ai-drug-discovery)**: A massive dataset of chemical simulations to train AI models for scientific research.
- Tesla
	- Autopilot
	- Innovating with AI for advanced driver-assistance systems.
	- Self-Driving Cars
	- Pioneering autonomous vehicle technology with sophisticated AI algorithms.
	- Grok (LLM)
		- A witty and satirical AI chatbot that pulls in real-time information, Grok signifies Tesla's expansion into AI-driven communication.
- NVIDIA
	- AI Hardware
	- Designing cutting-edge GPUs and systems to power AI computing.
	- GPUs
	- Accelerating AI with powerful graphics processing units.
	- Data Centers
	- Building AI-[[Infrastructure]] to support the increasing demands of machine learning workloads.
	- Autonomous Vehicles
	- Contributing to the AI ecosystem with technology for self-driving vehicles.
	- Salesforce
	- CRM with Predictive Analytics
	- Integrating AI to anticipate customer needs and enhance engagement.
	- Chatbots
	- Improving customer service with AI-powered chatbots.
	- Marketing Automation
	- Leveraging AI to automate and personalize marketing campaigns.
- Adobe
	- Creative Software with AI
	- Infusing AI into creative software to augment the design process.
	- Photoshop
		- Using AI to streamline complex editing tasks with intuitive tools.
	- Illustrator
		- AI assists in creating vector graphics with precision and ease.
- **Notable Minors**
	- Channel 1
		- AI News with translation of footage {{tweet https://twitter.com/channel1_ai/status/1734591810033373231}}
-

	- ### AI's Expanding Role in Science and Medicine
		- AI's integration into scientific research and healthcare is accelerating. Notable applications include advanced weather forecasting systems like GraphCast and improved material discovery algorithms such as GNoME.  ([Top 10 Takeaways from Stanford’s 2024 AI Index Report](https://www.unite.ai/top-10-takeaways-from-stanfords-ai-index-report-2024/?utm_source=chatgpt.com), [The 2024 AI Index Report | Stanford HAI](https://hai.stanford.edu/ai-index/2024-ai-index-report?utm_source=chatgpt.com))

	- ### Drug Discovery Case Study
		- Microsoft collaborated with the Global Health Drug Discovery Institute (GHDDI) and the Gates Foundation on molecules to combat tuberculosis and coronaviruses.
		- They used a transformer model trained on SMILES strings (a way to represent molecules as text) to generate new molecule candidates.
		- The model was informed by the 3D geometry of the protein binding site.
		- A variational autoencoder was used to optimise existing molecules.
		- This approach led to the discovery of a molecule with more than two orders of magnitude stronger binding affinity to the target protein in just five months compared to several years using traditional methods.
		- The molecule was synthesised and tested at GHDDI, confirming its properties.
		- [GHDDI and Microsoft Research Use AI Technology to Achieve Significant Progress in Discovering New Drugs to Treat Global Infectious Diseases](https://www.microsoft.com/en-us/research/blog/ghddi-and-microsoft-research-use-ai-technology-to-achieve-significant-progress-in-discovering-new-drugs-to-treat-global-infectious-diseases/?msockid=35739e94ab6c69d41b738b93aa076831)
		- The team also considers practical aspects such as manufacturability, absorption, metabolism, excretion, and toxicity (ADMET).
		- AI is used to optimise these factors, focusing on bottlenecks in the drug discovery pipeline.
		- AI architectures, particularly those inspired by natural language processing (NLP) models, are demonstrating remarkable potential in handling vast datasets and intricate interactions within biological systems. These AI models are poised to accelerate scientific discovery by tackling challenges that traditional methods have struggled to address effectively.
		- Biological systems are characterized by intricate interplay of DNA, RNA, proteins, and small molecules within cells and organisms. Deciphering the complex interactions between these components is a grand challenge in biomedical science. Traditional analytical methods are not well-suited to the complexity of biological systems, leaving much more unknown than known about how cells, tissues, and bodies function at higher levels.
		- Modern AI architectures are very well suited to take advantage of biology's massive datasets, and a new wave of AI models are dramatically accelerating the process of scientific discovery in biology. These models are starting with understanding protein and other cellular structures and the physical interactions between them, and will likely soon zoom out to help understand how cells, tissues, and bodies function at higher levels.

		- ## Practical Applications and Workflows
			- These advanced AI models can be integrated into practical workflows for drug discovery and protein engineering. For example, to design a protein inhibitor, the workflow may involve identifying a problematic protein-protein interaction, extracting the interaction motif using RF Diffusion, scaffolding a new protein structure incorporating the motif, optimizing the structure using Partial Diffusion and Ligand and PNN, and validating the interaction using AlphaFold Multimer.
			- The speed and efficiency of these models allow for rapid iteration and generation of many potential candidates with high accuracy and effectiveness. Hundreds or thousands of backbones can be designed, and hundreds or thousands of sequences can be designed for each backbone using Ligand and PNN in a matter of minutes. When synthesized and tested, these designed proteins often demonstrate high thermal stability, specificity, and binding affinity.

		- ## Bottlenecks in Drug Discovery
			- Despite the remarkable advancements, there are challenges and bottlenecks in the adoption of AI models in biological research. Target identification remains a significant challenge in drug discovery. The rapid evolution of the field and technical barriers, such as the requirement for programming skills and familiarity with computational environments, can hinder the widespread adoption of these models by researchers without a programming background. This is potentially an opportunity.

- # The (near) Future
	- The integration of AI in biological research holds immense potential for advancing scientific discovery, improving human health, extending lifespan, and enhancing quality of life. As these technologies continue to evolve, they may lead to a paradigm shift in how we think about health, longevity, and our relationship with the environment.
	- The ability to cure a wide range of diseases and significantly extend human lifespan could potentially lead to a shift in human consciousness, prompting a deeper appreciation for life, health, and interconnectedness.
- [Moderna partners with OpenAI to accelerate the development of life-saving treatments - YouTube](https://www.youtube.com/watch?v=t3UHnKLVS1M)
-

	- ## Healthcare and Medicine
		- AI streamlining healthcare administration and patient care, leading to efficient drug discovery and personalized medicine.
		  background-color:: green
		- AI's expanded role in telemedicine and remote patient monitoring.
		  background-color:: green

	- ### Research
		- **[Open Molecules 2025](https://www.semafor.com/news/2025/05/21/meta-releases-huge-data-set-to-spur-ai-drug-discovery)**: A massive dataset of chemical simulations to train AI models for scientific research.
- Tesla
	- Autopilot
	- Innovating with AI for advanced driver-assistance systems.
	- Self-Driving Cars
	- Pioneering autonomous vehicle technology with sophisticated AI algorithms.
	- Grok (LLM)
		- A witty and satirical AI chatbot that pulls in real-time information, Grok signifies Tesla's expansion into AI-driven communication.
- NVIDIA
	- AI Hardware
	- Designing cutting-edge GPUs and systems to power AI computing.
	- GPUs
	- Accelerating AI with powerful graphics processing units.
	- Data Centers
	- Building AI-[[Infrastructure]] to support the increasing demands of machine learning workloads.
	- Autonomous Vehicles
	- Contributing to the AI ecosystem with technology for self-driving vehicles.
	- Salesforce
	- CRM with Predictive Analytics
	- Integrating AI to anticipate customer needs and enhance engagement.
	- Chatbots
	- Improving customer service with AI-powered chatbots.
	- Marketing Automation
	- Leveraging AI to automate and personalize marketing campaigns.
- Adobe
	- Creative Software with AI
	- Infusing AI into creative software to augment the design process.
	- Photoshop
		- Using AI to streamline complex editing tasks with intuitive tools.
	- Illustrator
		- AI assists in creating vector graphics with precision and ease.
- **Notable Minors**
	- Channel 1
		- AI News with translation of footage {{tweet https://twitter.com/channel1_ai/status/1734591810033373231}}
-

	- ### AI's Expanding Role in Science and Medicine
		- AI's integration into scientific research and healthcare is accelerating. Notable applications include advanced weather forecasting systems like GraphCast and improved material discovery algorithms such as GNoME.  ([Top 10 Takeaways from Stanford’s 2024 AI Index Report](https://www.unite.ai/top-10-takeaways-from-stanfords-ai-index-report-2024/?utm_source=chatgpt.com), [The 2024 AI Index Report | Stanford HAI](https://hai.stanford.edu/ai-index/2024-ai-index-report?utm_source=chatgpt.com))

	- ### Drug Discovery Case Study
		- Microsoft collaborated with the Global Health Drug Discovery Institute (GHDDI) and the Gates Foundation on molecules to combat tuberculosis and coronaviruses.
		- They used a transformer model trained on SMILES strings (a way to represent molecules as text) to generate new molecule candidates.
		- The model was informed by the 3D geometry of the protein binding site.
		- A variational autoencoder was used to optimise existing molecules.
		- This approach led to the discovery of a molecule with more than two orders of magnitude stronger binding affinity to the target protein in just five months compared to several years using traditional methods.
		- The molecule was synthesised and tested at GHDDI, confirming its properties.
		- [GHDDI and Microsoft Research Use AI Technology to Achieve Significant Progress in Discovering New Drugs to Treat Global Infectious Diseases](https://www.microsoft.com/en-us/research/blog/ghddi-and-microsoft-research-use-ai-technology-to-achieve-significant-progress-in-discovering-new-drugs-to-treat-global-infectious-diseases/?msockid=35739e94ab6c69d41b738b93aa076831)
		- The team also considers practical aspects such as manufacturability, absorption, metabolism, excretion, and toxicity (ADMET).
		- AI is used to optimise these factors, focusing on bottlenecks in the drug discovery pipeline.
		- AI architectures, particularly those inspired by natural language processing (NLP) models, are demonstrating remarkable potential in handling vast datasets and intricate interactions within biological systems. These AI models are poised to accelerate scientific discovery by tackling challenges that traditional methods have struggled to address effectively.
		- Biological systems are characterized by intricate interplay of DNA, RNA, proteins, and small molecules within cells and organisms. Deciphering the complex interactions between these components is a grand challenge in biomedical science. Traditional analytical methods are not well-suited to the complexity of biological systems, leaving much more unknown than known about how cells, tissues, and bodies function at higher levels.
		- Modern AI architectures are very well suited to take advantage of biology's massive datasets, and a new wave of AI models are dramatically accelerating the process of scientific discovery in biology. These models are starting with understanding protein and other cellular structures and the physical interactions between them, and will likely soon zoom out to help understand how cells, tissues, and bodies function at higher levels.

		- ## Practical Applications and Workflows
			- These advanced AI models can be integrated into practical workflows for drug discovery and protein engineering. For example, to design a protein inhibitor, the workflow may involve identifying a problematic protein-protein interaction, extracting the interaction motif using RF Diffusion, scaffolding a new protein structure incorporating the motif, optimizing the structure using Partial Diffusion and Ligand and PNN, and validating the interaction using AlphaFold Multimer.
			- The speed and efficiency of these models allow for rapid iteration and generation of many potential candidates with high accuracy and effectiveness. Hundreds or thousands of backbones can be designed, and hundreds or thousands of sequences can be designed for each backbone using Ligand and PNN in a matter of minutes. When synthesized and tested, these designed proteins often demonstrate high thermal stability, specificity, and binding affinity.

		- ## Bottlenecks in Drug Discovery
			- Despite the remarkable advancements, there are challenges and bottlenecks in the adoption of AI models in biological research. Target identification remains a significant challenge in drug discovery. The rapid evolution of the field and technical barriers, such as the requirement for programming skills and familiarity with computational environments, can hinder the widespread adoption of these models by researchers without a programming background. This is potentially an opportunity.

- # The (near) Future
	- The integration of AI in biological research holds immense potential for advancing scientific discovery, improving human health, extending lifespan, and enhancing quality of life. As these technologies continue to evolve, they may lead to a paradigm shift in how we think about health, longevity, and our relationship with the environment.
	- The ability to cure a wide range of diseases and significantly extend human lifespan could potentially lead to a shift in human consciousness, prompting a deeper appreciation for life, health, and interconnectedness.
- [Moderna partners with OpenAI to accelerate the development of life-saving treatments - YouTube](https://www.youtube.com/watch?v=t3UHnKLVS1M)
-

	- ## Healthcare and Medicine
		- AI streamlining healthcare administration and patient care, leading to efficient drug discovery and personalized medicine.
		  background-color:: green
		- AI's expanded role in telemedicine and remote patient monitoring.
		  background-color:: green

	- ### Research
		- **[Open Molecules 2025](https://www.semafor.com/news/2025/05/21/meta-releases-huge-data-set-to-spur-ai-drug-discovery)**: A massive dataset of chemical simulations to train AI models for scientific research.
- Tesla
	- Autopilot
	- Innovating with AI for advanced driver-assistance systems.
	- Self-Driving Cars
	- Pioneering autonomous vehicle technology with sophisticated AI algorithms.
	- Grok (LLM)
		- A witty and satirical AI chatbot that pulls in real-time information, Grok signifies Tesla's expansion into AI-driven communication.
- NVIDIA
	- AI Hardware
	- Designing cutting-edge GPUs and systems to power AI computing.
	- GPUs
	- Accelerating AI with powerful graphics processing units.
	- Data Centers
	- Building AI-[[Infrastructure]] to support the increasing demands of machine learning workloads.
	- Autonomous Vehicles
	- Contributing to the AI ecosystem with technology for self-driving vehicles.
	- Salesforce
	- Marketing Automation
	- Leveraging AI to automate and personalize marketing campaigns.
- Adobe
	- Creative Software with AI
		- AI assists in creating vector graphics with precision and ease.
- **Notable Minors**
	- Channel 1
		- AI News with translation of footage {{tweet https://twitter.com/channel1_ai/status/1734591810033373231}}

	- ### Drug Discovery Case Study
		- Microsoft collaborated with the Global Health Drug Discovery Institute (GHDDI) and the Gates Foundation on molecules to combat tuberculosis and coronaviruses.
		- The molecule was synthesised and tested at GHDDI, confirming its properties.
		- [GHDDI and Microsoft Research Use AI Technology to Achieve Significant Progress in Discovering New Drugs to Treat Global Infectious Diseases](https://www.microsoft.com/en-us/research/blog/ghddi-and-microsoft-research-use-ai-technology-to-achieve-significant-progress-in-discovering-new-drugs-to-treat-global-infectious-diseases/?msockid=35739e94ab6c69d41b738b93aa076831)
		- The team also considers practical aspects such as manufacturability, absorption, metabolism, excretion, and toxicity (ADMET).
		- AI is used to optimise these factors, focusing on bottlenecks in the drug discovery pipeline.
			- AlphaFold 2, developed by DeepMind, marked a significant breakthrough in protein structure prediction. This AI model can predict a static 3D structure from a protein sequence, providing confidence scores for the predicted structure. However, AlphaFold 2 has limitations in capturing protein dynamics, highlighting the need for models that can predict multiple conformations and their transitions.
			- Distributional Graph Former, building upon AlphaFold 2's architecture, predicts ensembles of protein structures and transition pathways. AlphaFlow, a diffusion model trained on molecular dynamics simulation data, generates multiple protein conformations. These advancements demonstrate the potential of AI in capturing the dynamic nature of proteins.

		- ## Bottlenecks in Drug Discovery
			- Despite the remarkable advancements, there are challenges and bottlenecks in the adoption of AI models in biological research. Target identification remains a significant challenge in drug discovery. The rapid evolution of the field and technical barriers, such as the requirement for programming skills and familiarity with computational environments, can hinder the widespread adoption of these models by researchers without a programming background. This is potentially an opportunity.

- # The (near) Future
	- The integration of AI in biological research holds immense potential for advancing scientific discovery, improving human health, extending lifespan, and enhancing quality of life. As these technologies continue to evolve, they may lead to a paradigm shift in how we think about health, longevity, and our relationship with the environment.
	- The ability to cure a wide range of diseases and significantly extend human lifespan could potentially lead to a shift in human consciousness, prompting a deeper appreciation for life, health, and interconnectedness.
- [Moderna partners with OpenAI to accelerate the development of life-saving treatments - YouTube](https://www.youtube.com/watch?v=t3UHnKLVS1M)
-

	- ### Virtual Labs and Scientific Research:

		- ## Bottlenecks in Drug Discovery
			- Despite the remarkable advancements, there are challenges and bottlenecks in the adoption of AI models in biological research. Target identification remains a significant challenge in drug discovery. The rapid evolution of the field and technical barriers, such as the requirement for programming skills and familiarity with computational environments, can hinder the widespread adoption of these models by researchers without a programming background. This is potentially an opportunity.

- # Agents in Biological Research
	- AI agents have the potential to transform biological research by automating tasks such as literature review, hypothesis generation, experimental design, and data analysis. Companies like Future House are developing AI agents that can identify potential drug targets and design experiments, significantly accelerating the process of discovery. These agents, powered by large language models (LLMs) and other AI technologies, can review thousands of research papers, develop targets or hypotheses to test, and even drive autonomous labs.
	- As these AI agents become more capable, they may play a crucial role in guiding research and helping humans navigate the complex landscape of biological data and interactions. The convergence of AI agents with specific tools for designing molecules, proteins, and nucleic acids could lead to rapid progress in solving challenging problems in biology and medicine.
-

	- ### Drug Discovery Case Study
		- Microsoft collaborated with the Global Health Drug Discovery Institute (GHDDI) and the Gates Foundation on molecules to combat tuberculosis and coronaviruses.
		- The molecule was synthesised and tested at GHDDI, confirming its properties.
			- Training models to predict binding affinity and protein interactions is a challenging task. Overfitting is a common issue, where models perform well on training data but fail to generalize to new data. Proper data splitting based on sequence and structural similarity is crucial to ensure the model's ability to generalize to unseen data. This is particularly challenging for protein interaction models, where similar sequences might be present in both training and testing sets, leading to overfitting and poor generalization.
			- These advanced AI models can be integrated into practical workflows for drug discovery and protein engineering. For example, to design a protein inhibitor, the workflow may involve identifying a problematic protein-protein interaction, extracting the interaction motif using RF Diffusion, scaffolding a new protein structure incorporating the motif, optimizing the structure using Partial Diffusion and Ligand and PNN, and validating the interaction using AlphaFold Multimer.
			- The speed and efficiency of these models allow for rapid iteration and generation of many potential candidates with high accuracy and effectiveness. Hundreds or thousands of backbones can be designed, and hundreds or thousands of sequences can be designed for each backbone using Ligand and PNN in a matter of minutes. When synthesized and tested, these designed proteins often demonstrate high thermal stability, specificity, and binding affinity.

		- ## Bottlenecks in Drug Discovery
			- Despite the remarkable advancements, there are challenges and bottlenecks in the adoption of AI models in biological research. Target identification remains a significant challenge in drug discovery. The rapid evolution of the field and technical barriers, such as the requirement for programming skills and familiarity with computational environments, can hinder the widespread adoption of these models by researchers without a programming background. This is potentially an opportunity.

## Core Characteristics

- **Molecular Design**: De novo drug design and lead optimisation
- **Virtual Screening**: High-throughput computational screening of compound libraries
- **Target Prediction**: Identification of disease-relevant biological targets
- **ADMET Prediction**: Absorption, distribution, metabolism, excretion, toxicity forecasting
- **Clinical Trial Design**: Patient stratification and endpoint prediction

## Relationships

- **Superclass**: Medical AI
- **Related**: Cheminformatics, Bioinformatics, Molecular Modelling
- **Utilises**: Graph Neural Networks, Generative Models, Reinforcement Learning

## Technical Implementation

```python
import torch
import torch.nn as nn
from rdkit import Chem
from rdkit.Chem import Descriptors
from typing import List, Dict, Tuple

class DrugDiscoveryAI:
    """AI system for drug discovery and molecular design"""

    def __init__(self):
        self.molecular_property_predictor = self._load_property_model()
        self.generative_model = self._load_generative_model()

    def predict_molecular_properties(
        self,
        smiles: str
    ) -> Dict[str, float]:
        """Predict drug-like properties from SMILES notation"""
        mol = Chem.MolFromSmiles(smiles)

        properties = {
            'molecular_weight': Descriptors.MolWt(mol),
            'logP': Descriptors.MolLogP(mol),
            'hbd': Descriptors.NumHDonors(mol),
            'hba': Descriptors.NumHAcceptors(mol),
            'tpsa': Descriptors.TPSA(mol),
            'rotatable_bonds': Descriptors.NumRotatableBonds(mol)
        }

        # Lipinski's Rule of Five
        properties['lipinski_violations'] = sum([
            properties['molecular_weight'] > 500,
            properties['logP'] > 5,
            properties['hbd'] > 5,
            properties['hba'] > 10
        ])

        # AI-predicted properties
        properties['bioavailability'] = self._predict_bioavailability(mol)
        properties['toxicity_score'] = self._predict_toxicity(mol)
        properties['binding_affinity'] = self._predict_binding_affinity(mol)

        return properties

    def generate_drug_candidates(
        self,
        target_properties: Dict,
        num_candidates: int = 100
    ) -> List[str]:
        """Generate novel drug candidates with desired properties"""
        candidates = []

        for _ in range(num_candidates):
            # Generate SMILES using generative model
            smiles = self._generate_smiles(target_properties)

            # Validate and check properties
            if self._is_valid_drug_candidate(smiles, target_properties):
                candidates.append(smiles)

        return candidates

    def _predict_bioavailability(self, mol) -> float:
        """Predict oral bioavailability"""
        # Simplified - would use trained ML model
        return 0.75

    def _predict_toxicity(self, mol) -> float:
        """Predict toxicity score"""
        # Simplified - would use QSAR model
        return 0.2

    def _predict_binding_affinity(self, mol) -> float:
        """Predict target binding affinity"""
        # Simplified - would use docking or ML model
        return -8.5

    def _load_property_model(self) -> nn.Module:
        """Load molecular property prediction model"""
        return nn.Sequential()

    def _load_generative_model(self) -> nn.Module:
        """Load generative model for molecular design"""
        return nn.Sequential()

    def _generate_smiles(self, target_properties: Dict) -> str:
        """Generate SMILES notation for novel molecule"""
        # Simplified - would use VAE or GAN
        return "CC(C)CC1=CC=C(C=C1)C(C)C(=O)O"

    def _is_valid_drug_candidate(
        self,
        smiles: str,
        target_properties: Dict
    ) -> bool:
        """Validate drug candidate against target properties"""
        mol = Chem.MolFromSmiles(smiles)
        if mol is None:
            return False

        props = self.predict_molecular_properties(smiles)

        # Check Lipinski violations
        if props['lipinski_violations'] > 1:
            return False

        # Check target constraints
        for prop, target_value in target_properties.items():
            if prop in props:
                if abs(props[prop] - target_value) > target_value * 0.2:
                    return False

        return True


# Example usage
if __name__ == "__main__":
    drug_ai = DrugDiscoveryAI()

    # Analyse existing molecule
    aspirin_smiles = "CC(=O)OC1=CC=CC=C1C(=O)O"
    properties = drug_ai.predict_molecular_properties(aspirin_smiles)
    print(f"Aspirin properties: {properties}")

    # Generate new candidates
    target_props = {
        'molecular_weight': 350,
        'logP': 3.0,
        'bioavailability': 0.8
    }
    candidates = drug_ai.generate_drug_candidates(target_props, num_candidates=10)
    print(f"Generated {len(candidates)} drug candidates")
```

## Applications

1. **De Novo Drug Design**: Generation of novel molecular structures
2. **Virtual Screening**: Computational screening of compound libraries
3. **Lead Optimisation**: Optimisation of drug candidate properties
4. **Target Identification**: Discovery of disease-relevant targets
5. **Drug Repurposing**: Identification of new uses for existing drugs
6. **Toxicity Prediction**: Early-stage safety assessment
7. **Clinical Trial Design**: Patient selection and outcome prediction
8. **Formulation Optimisation**: Drug delivery system design

## Key Literature

1. Vamathevan, J., et al. (2019). "Applications of machine learning in drug discovery and development." *Nature Reviews Drug Discovery*, 18(6), 463-477.

2. Schneider, P., et al. (2020). "Rethinking drug design in the artificial intelligence era." *Nature Reviews Drug Discovery*, 19(5), 353-364.

3. Stokes, J. M., et al. (2020). "A deep learning approach to antibiotic discovery." *Cell*, 180(4), 688-702.

4. Zhavoronkov, A., et al. (2019). "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 37(9), 1038-1040.

## See Also

- [[Medical AI]]
- [[Molecular Design]]
- [[Generative Models]]
- [[Graph Neural Network]]

## Metadata

- **Domain**: Drug Discovery, Pharmaceutical Research
- **Maturity**: Research and early commercial deployment
	-
	- ### Original Content
	  collapsed:: true
		- ```
# Drug Discovery AI
		  
		  **Term ID**: AI-0341
		  **Category**: Domain Applications → Medical AI
		  **Status**: Stable
		  **Last Updated**: 2025-10-27
		  
		  ## Definition
		  
		  Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.
		  
		  ## Core Characteristics
		  
		  - **Molecular Design**: De novo drug design and lead optimisation
		  - **Virtual Screening**: High-throughput computational screening of compound libraries
		  - **Target Prediction**: Identification of disease-relevant biological targets
		  - **ADMET Prediction**: Absorption, distribution, metabolism, excretion, toxicity forecasting
		  - **Clinical Trial Design**: Patient stratification and endpoint prediction
		  
		  ## Relationships
		  
		  - **Superclass**: Medical AI
		  - **Related**: Cheminformatics, Bioinformatics, Molecular Modelling
		  - **Utilises**: Graph Neural Networks, Generative Models, Reinforcement Learning
		  
		  ## Technical Implementation
		  
		  ```python
		  import torch
		  import torch.nn as nn
		  from rdkit import Chem
		  from rdkit.Chem import Descriptors
		  from typing import List, Dict, Tuple
		  
		  class DrugDiscoveryAI:
		      """AI system for drug discovery and molecular design"""
		  
		      def __init__(self):
		          self.molecular_property_predictor = self._load_property_model()
		          self.generative_model = self._load_generative_model()
		  
		      def predict_molecular_properties(
		          self,
		          smiles: str
		      ) -> Dict[str, float]:
		          """Predict drug-like properties from SMILES notation"""
		          mol = Chem.MolFromSmiles(smiles)
		  
		          properties = {
		              'molecular_weight': Descriptors.MolWt(mol),
		              'logP': Descriptors.MolLogP(mol),
		              'hbd': Descriptors.NumHDonors(mol),
		              'hba': Descriptors.NumHAcceptors(mol),
		              'tpsa': Descriptors.TPSA(mol),
		              'rotatable_bonds': Descriptors.NumRotatableBonds(mol)
		          }
		  
		          # Lipinski's Rule of Five
		          properties['lipinski_violations'] = sum([
		              properties['molecular_weight'] > 500,
		              properties['logP'] > 5,
		              properties['hbd'] > 5,
		              properties['hba'] > 10
		          ])
		  
		          # AI-predicted properties
		          properties['bioavailability'] = self._predict_bioavailability(mol)
		          properties['toxicity_score'] = self._predict_toxicity(mol)
		          properties['binding_affinity'] = self._predict_binding_affinity(mol)
		  
		          return properties
		  
		      def generate_drug_candidates(
		          self,
		          target_properties: Dict,
		          num_candidates: int = 100
		      ) -> List[str]:
		          """Generate novel drug candidates with desired properties"""
		          candidates = []
		  
		          for _ in range(num_candidates):
		              # Generate SMILES using generative model
		              smiles = self._generate_smiles(target_properties)
		  
		              # Validate and check properties
		              if self._is_valid_drug_candidate(smiles, target_properties):
		                  candidates.append(smiles)
		  
		          return candidates
		  
		      def _predict_bioavailability(self, mol) -> float:
		          """Predict oral bioavailability"""
		          # Simplified - would use trained ML model
		          return 0.75
		  
		      def _predict_toxicity(self, mol) -> float:
		          """Predict toxicity score"""
		          # Simplified - would use QSAR model
		          return 0.2
		  
		      def _predict_binding_affinity(self, mol) -> float:
		          """Predict target binding affinity"""
		          # Simplified - would use docking or ML model
		          return -8.5
		  
		      def _load_property_model(self) -> nn.Module:
		          """Load molecular property prediction model"""
		          return nn.Sequential()
		  
		      def _load_generative_model(self) -> nn.Module:
		          """Load generative model for molecular design"""
		          return nn.Sequential()
		  
		      def _generate_smiles(self, target_properties: Dict) -> str:
		          """Generate SMILES notation for novel molecule"""
		          # Simplified - would use VAE or GAN
		          return "CC(C)CC1=CC=C(C=C1)C(C)C(=O)O"
		  
		      def _is_valid_drug_candidate(
		          self,
		          smiles: str,
		          target_properties: Dict
		      ) -> bool:
		          """Validate drug candidate against target properties"""
		          mol = Chem.MolFromSmiles(smiles)
		          if mol is None:
		              return False
		  
		          props = self.predict_molecular_properties(smiles)
		  
		          # Check Lipinski violations
		          if props['lipinski_violations'] > 1:
		              return False
		  
		          # Check target constraints
		          for prop, target_value in target_properties.items():
		              if prop in props:
		                  if abs(props[prop] - target_value) > target_value * 0.2:
		                      return False
		  
		          return True
		  
		  
		  # Example usage
		  if __name__ == "__main__":
		      drug_ai = DrugDiscoveryAI()
		  
		      # Analyse existing molecule
		      aspirin_smiles = "CC(=O)OC1=CC=CC=C1C(=O)O"
		      properties = drug_ai.predict_molecular_properties(aspirin_smiles)
		      print(f"Aspirin properties: {properties}")
		  
		      # Generate new candidates
		      target_props = {
		          'molecular_weight': 350,
		          'logP': 3.0,
		          'bioavailability': 0.8
		      }
		      candidates = drug_ai.generate_drug_candidates(target_props, num_candidates=10)
		      print(f"Generated {len(candidates)} drug candidates")
		  ```
		  
		  ## Applications
		  
		  1. **De Novo Drug Design**: Generation of novel molecular structures
		  2. **Virtual Screening**: Computational screening of compound libraries
		  3. **Lead Optimisation**: Optimisation of drug candidate properties
		  4. **Target Identification**: Discovery of disease-relevant targets
		  5. **Drug Repurposing**: Identification of new uses for existing drugs
		  6. **Toxicity Prediction**: Early-stage safety assessment
		  7. **Clinical Trial Design**: Patient selection and outcome prediction
		  8. **Formulation Optimisation**: Drug delivery system design
		  
		  ## Key Literature
		  
		  1. Vamathevan, J., et al. (2019). "Applications of machine learning in drug discovery and development." *Nature Reviews Drug Discovery*, 18(6), 463-477.
		  
		  2. Schneider, P., et al. (2020). "Rethinking drug design in the artificial intelligence era." *Nature Reviews Drug Discovery*, 19(5), 353-364.
		  
		  3. Stokes, J. M., et al. (2020). "A deep learning approach to antibiotic discovery." *Cell*, 180(4), 688-702.
		  
		  4. Zhavoronkov, A., et al. (2019). "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 37(9), 1038-1040.
		  
		  ## See Also
		  
		  - [[Medical AI]]
		  - [[Molecular Design]]
		  - [[Generative Models]]
		  - [[Graph Neural Network]]
		  
		  ## Metadata
		  
		  - **Domain**: Drug Discovery, Pharmaceutical Research
		  - **Maturity**: Research and early commercial deployment
		  
		  ```

    - uses-technique:: [[Generative Models]], [[Graph Neural Network]]

- public-access:: true
	- definition:: Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.



## Academic Context

- Drug Discovery AI refers to artificial intelligence systems designed to accelerate pharmaceutical research and development by automating and optimising key processes such as molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation.
  - These systems integrate cheminformatics, molecular modelling, and advanced machine learning techniques to reduce drug development timelines and costs while improving success rates.
  - The academic foundation lies in computational chemistry, bioinformatics, and machine learning, evolving from traditional hypothesis-driven methods towards holistic, data-driven AI platforms that model complex biological systems beyond classical reductionism.
  - Key developments include the shift from modular, task-specific tools to end-to-end AI-enabled platforms capable of integrating multimodal biological and chemical data for comprehensive drug discovery workflows[1][4].

## Current Landscape (2025)

- Industry adoption of Drug Discovery AI is widespread, with platforms increasingly deployed across pharmaceutical companies, biotech firms, and academic institutions.
  - Notable organisations include NVIDIA, Xaira Therapeutics, Recursion, and Generate: Biomedicines, which leverage generative AI and multimodal data integration to identify novel drug candidates and optimise clinical trials[2].
  - The US FDA recognises and regulates AI applications throughout the drug product lifecycle, reflecting growing integration in nonclinical, clinical, manufacturing, and postmarketing phases[3].
- Technical capabilities now encompass:
  - Generative AI for novel molecular structure creation.
  - Machine learning models for toxicity and efficacy prediction.
  - Virtual cell models simulating complex biological interactions.
  - Natural language processing to mine vast biomedical literature.
- Limitations remain in data quality, model interpretability, and regulatory acceptance, necessitating rigorous validation and standardisation.
- Emerging standards and frameworks include FDA guidances on AI use in regulatory decision-making and manufacturing, and industry initiatives for transparency and reproducibility[3][6].

## Research & Literature

- Key academic sources include:
  - Vamathevan et al. (2025), "AI-Driven Drug Discovery: A Comprehensive Review," ACS Omega, 10(23), 23889–23903. DOI: 10.1021/acsomega.5c00549 — a critical analysis of AI/ML methodologies across drug discovery phases, emphasising cloud-based implementations and model validation[4].
  - Barzilay et al. (2025), "Multimodal AI for Health Care," presented at The State of AI in Drug Discovery Summit — highlighting integration of diverse biological data for drug candidate identification[2].
- Ongoing research focuses on:
  - Enhancing AI interpretability and explainability.
  - Integrating real-world data and digital health technologies.
  - Developing AI models that simulate human biology more accurately.
  - Addressing ethical and regulatory challenges in AI deployment[1][3][4].

## UK Context

- The UK is a significant contributor to Drug Discovery AI, with strong academic and industrial ecosystems.
  - Centres of excellence in North England include:
    - Manchester Institute of Biotechnology, leveraging AI for molecular design and target validation.
    - Leeds Institute of Biomedical and Clinical Sciences, focusing on AI-driven clinical trial optimisation.
    - Newcastle University’s Centre for AI and Data Analytics in Health, advancing AI applications in drug safety prediction.
    - Sheffield’s Advanced Manufacturing Research Centre, integrating AI with automated drug manufacturing processes.
  - Collaborative initiatives between academia, NHS trusts, and biotech companies foster innovation and translation of AI discoveries into clinical practice.
- UK government and funding bodies actively support AI in life sciences through programmes like UKRI’s AI for Health and the Medicines Discovery Catapult, with a focus on regional development and commercialisation.

## Future Directions

- Emerging trends include:
  - Expansion of generative AI capabilities to explore vast chemical spaces with unprecedented creativity.
  - Integration of AI with digital twins and virtual patients to simulate clinical outcomes more accurately.
  - Increased use of federated learning to leverage distributed datasets while preserving privacy.
- Anticipated challenges:
  - Ensuring data quality, diversity, and representativeness to avoid bias.
  - Navigating evolving regulatory landscapes and ethical considerations.
  - Balancing automation with human expertise to maintain scientific rigour.
- Research priorities focus on:
  - Developing robust, interpretable AI models.
  - Enhancing collaboration across disciplines and sectors.
  - Scaling AI solutions for rare diseases and personalised medicine.
- One might say the future of Drug Discovery AI is less about replacing scientists and more about giving them a faster, smarter lab assistant—minus the coffee breaks.

## References

1. BiopharmaTrend. (2025). Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025. BiopharmaTrend.  
2. Barzilay, R., Lowe, D., Lundberg, E., et al. (2025). The State of AI in Drug Discovery 2025. Genetic Engineering & Biotechnology News.  
3. U.S. Food and Drug Administration. (2025). Artificial Intelligence for Drug Development. FDA CDER.  
4. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2025). AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega, 10(23), 23889–23903. https://doi.org/10.1021/acsomega.5c00549  
5. Lifebit. (2025). AI Driven Drug Discovery: 5 Powerful Breakthroughs in 2025. Lifebit Blog.  
6. ELRIG. (2025). Inside ELRIG's Drug Discovery 2025: Automation, AI and Human-Relevant Models. Drug Target Review.


## Metadata

- **Last Updated**: 2025-11-11
- **Review Status**: Comprehensive editorial review
- **Verification**: Academic sources verified
- **Regional Context**: UK/North England where applicable
